Newsletter sign-up

RESI Conference - San Francisco
Tuesday, 9 January 2018

We are looking forward to the RESI conference, where we will present our exciting growth opportunity to investors and other interested parties

Biologics Symposium - Copenhagen
Tuesday, 16 January 2018

As an active member of the biologics and regenerative medicine community, we are looking forward to the discussions at this meeting

Biotech & Money - London
Monday, 5 February 2018

Our CEO, Graeme Brookes, is an invited panel member for the CEO Panel discussion during the meeting

Bio-Europe Spring - Amsterdam
Monday, 12 February 2018

We look forward to discussing our unique investment opportunity at this key event

DK Bio - Boston
Tuesday, 10 April 2018

Once again, we look forward to being part of continuing to build and strengthen Danish-US life science connections

SAWC - Charlotte
Wednesday, 25 April 2018

We look forward to seeing friends and contacts at the SAWC

EWMA - Krakow
Wednesday, 9 May 2018

We will attend the whole conference and will also present at the ‘New Technologies in Wound Care’ Symposium in the Budapest Room at the congress centre on Thursday, May 10th 16.00 - 17.00

< Back to overview

Reapplix announces new US FDA 510(k) clearance for expanded system, including automated centrifuge, a further advancement of its regenerative wound care technology

by Rasmus Lundquist

Reapplix today announced that it has received US FDA 510(k) clearance for its 3C Patch System® including the 3CP Centrifuge.

This new 510(k) clearance expands the 3C Patch System® to include Reapplix’s new 3CP Centrifuge, which features optical sensors and automates the process of producing a 3C Patch®. This further improves usability as health care professionals now need just a few minutes’ hands on time to prepare the 3C Patch.

The proprietary 3C Patch Centrifuge further enhances the simple-to-use 3C Patch® device technology and has been cleared for the following indications for use: “The 3C Patch System® is intended to be used at point-of-care for the safe and rapid preparation of platelet-rich plasma (PRP) gel from a small sample of a patient’s own peripheral blood. Under the supervision of a healthcare professional, the PRP gel produced by the 3C Patch System® is topically applied for the management of exuding cutaneous wounds, such as leg ulcers, pressure ulcers, and diabetic ulcers and mechanically or surgically-debrided wounds.”Reapplix Press release - 510(k) for expanded System April 2017

Top